Physician profile
Mitchell Hare
NPI 1124654256
$1,848.93
in general payments reported to CMS, 2019-2025
12 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $352 · 2024: $1,179 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.94 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $582.95 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $330.76 | 2024-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $266.36 | 2023-2024 | Verquvo, Gardasil 9, Capvaxive |
| Abbvie INC. | $179.76 | 2023-2025 | |
| Daiichi Sankyo INC. | $148.72 | 2023-2025 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $103.72 | 2023-2024 | Farxiga |
| Scpharmaceuticals INC. | $59.41 | 2024 | |
| Janssen Pharmaceuticals, INC | $54.86 | 2024 | Xarelto |
| Pfizer INC. | $44.33 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $37.78 | 2024 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $25.88 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.